Kim So-yeon, CEO of the South Korean company PCL, announced at a press conference that the company is in advanced talks with Moroccan authorities to introduce its groundbreaking smart device, “HiSU,” to Morocco.
The “HiSU” device is designed to detect high-risk viruses in blood, addressing key challenges in blood transfusion safety. PCL, which specializes in in vitro diagnostic medical devices for immunological diagnosis, is also pursuing licensing and supplementary agreements in Russia and Austria.
The device is notable for its ability to screen up to 540 blood samples within four hours. It can diagnose severe infections such as HIV, hepatitis B and C, and syphilis. Additionally, “HiSU” can separate blood into its various components—red blood cells, white blood cells, platelets, and other necessary elements for transfusions.
This technology is especially crucial for Africa, where many countries face severe blood transfusion issues due to a lack of equipment and insufficient staff. This often leads to the loss of collected blood due to undetected viruses.
Founded in 2008, PCL is a leader in multiplex immunodiagnostics and has pioneered the first multiplex immunodiagnostic product capable of diagnosing up to 64 diseases simultaneously.
add your comment
Terms of publication : Not to offend the writer, people, sacred things, or attack religions or the divine self, and refrain from racist incitement and insults.